Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of at least 80 as they launch their largest climbs.
See How IBD Helps You Make More Money In Stocks
Is Akero Therapeutics Stock A Buy?
Akero Therapeutics stock gapped up Tuesday on positive test results for a hepatitis treatment. The biotech stock is extended and is not currently near a potential buy zone. See if the stock goes on to form a chart pattern that could launch a new move.
The biotech stock posted 7% EPS growth last quarter. Revenue rose 0%.
Akero Therapeutics stock holds the No. 65 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Genmab and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
